3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
1217
Neoplasms
1027
Carcinoma, Non-Small-Cell Lung
749
Prostatic Neoplasms
688
Colorectal Neoplasms
593
Lung Neoplasms
573
Pancreatic Neoplasms
394
Leukemia, Myeloid, Acute
394
Neoplasm Metastasis
388
Ovarian Neoplasms
370
Multiple Myeloma
369
Stomach Neoplasms
316
Carcinoma, Hepatocellular
301
Melanoma
281
Brain Neoplasms
277
Recurrence
273
Squamous Cell Carcinoma of Head and Neck
269
Head and Neck Neoplasms
237
Endometrial Neoplasms
234
Glioblastoma
233
Triple Negative Breast Neoplasms
228
Uterine Cervical Neoplasms
221
Precursor Cell Lymphoblastic Leukemia-Lymphoma
221
Lymphoma
221
Sarcoma
201
Hematologic Neoplasms
199
Urinary Bladder Neoplasms
196
Esophageal Neoplasms
190
Carcinoma, Renal Cell
188
Lymphoma, Non-Hodgkin
176
Interventions
Alpelisib
2
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphatic Abnormalities
×
1 year
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled